SUPN · Supernus Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $207.71M | - | $192.10M | $165.45M | $149.82M | - | $175.69M | $168.32M | $143.64M | $153.88M |
| Cost of Revenue | $23.39M | - | $18.96M | $16.83M | $15.76M | - | $17.58M | $17.92M | $16.31M | $19.60M |
| Gross Profit | $184.31M | - | $173.14M | $148.63M | $134.06M | - | $158.11M | $150.41M | $127.33M | $134.28M |
| R&D | $39.44M | - | $29.37M | $22.11M | $26.93M | - | $29.04M | $26.18M | $24.93M | $22.66M |
| SG&A | $125.17M | - | $179.68M | $93.55M | $89.94M | - | $69.75M | $85.90M | $86.52M | $82.70M |
| Total Operating Expenses | $216.04M | - | $252.33M | $153.31M | $160.08M | - | $134.84M | $145.76M | $146.80M | $145.74M |
| D&A | $26.13M | - | $500.0K | $500.0K | $20.38M | - | $600.0K | $600.0K | $20.75M | $600.0K |
| Operating Income | ($8.33M) | - | ($60.23M) | $12.14M | ($10.26M) | - | $40.84M | $22.57M | ($3.15M) | $8.14M |
| Interest Expense | - | - | - | - | - | - | $0 | $0 | $0 | $0 |
| Income Tax | ($3.66M) | - | ($12.84M) | ($5.83M) | $6.00M | - | $6.45M | $6.39M | $119.0K | $25.86M |
| Net Income | ($2.29M) | - | ($45.12M) | $22.50M | ($11.83M) | - | $38.50M | $19.92M | $124.0K | ($15.98M) |
| EPS - Basic | ($0.04) | - | ($0.80) | $0.40 | ($0.21) | - | $0.70 | $0.36 | $0.00 | ($0.29) |
| EPS - Diluted | ($0.04) | - | ($0.80) | $0.40 | ($0.21) | - | $0.69 | $0.36 | $0.00 | ($0.29) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $184.87M | $128.45M | $151.37M | $144.71M | $115.85M | $69.33M | $31.67M | $52.09M | $75.05M | $94.98M |
| Accounts Receivable | $182.18M | $187.80M | $171.25M | $140.83M | $145.64M | $142.08M | $145.41M | $152.49M | $147.73M | $141.76M |
| Inventory | $110.77M | $112.48M | $107.10M | $44.02M | $49.42M | $54.29M | $63.98M | $68.16M | $77.41M | $83.48M |
| Accounts Payable | $10.17M | $2.68M | $8.18M | $8.21M | $7.07M | $4.59M | $6.39M | $4.63M | $14.40M | $3.39M |
| Current Assets | $731.58M | $644.18M | $593.89M | $738.87M | $687.58M | $686.07M | $640.00M | $591.00M | $544.32M | $449.36M |
| Total Assets | $1.50B | $1.45B | $1.42B | $1.38B | $1.35B | $1.37B | $1.34B | $1.32B | $1.28B | $1.29B |
| Current Liabilities | $373.93M | $338.17M | $330.63M | $286.36M | $281.77M | $292.40M | $291.51M | $308.66M | $290.20M | $287.53M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $423.92M | $390.93M | $370.09M | $318.50M | $316.58M | $332.34M | $335.55M | $358.38M | $356.16M | $372.97M |
| Stockholders' Equity | $1.08B | $1.06B | $1.05B | $1.06B | $1.03B | $1.04B | $1.01B | $957.45M | $921.52M | $912.19M |
| Retained Earnings | $515.58M | $517.88M | $521.98M | $567.10M | $544.60M | $556.43M | $541.10M | $502.60M | $482.56M | $481.39M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $66.52M | - | - | - | $30.60M | - | - | - | $38.40M | - |
| Investing Cash Flow | ($19.22M) | - | - | - | $37.32M | - | - | - | ($51.62M) | - |
| Financing Cash Flow | $9.12M | - | - | - | ($21.40M) | - | - | - | $1.57M | - |
| CapEx | $0 | - | - | - | $327.0K | - | - | - | $248.0K | - |
| Free Cash Flow | $66.52M | - | - | - | $30.27M | - | - | - | $38.15M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 88.7% | - | 90.1% | 89.8% | 89.5% | - | 90.0% | 89.4% | 88.6% | 87.3% |
| Operating margin | -4.0% | - | -31.4% | 7.3% | -6.8% | - | 23.2% | 13.4% | -2.2% | 5.3% |
| EBITDA margin | 8.6% | - | -31.1% | 7.6% | 6.8% | - | 23.6% | 13.8% | 12.2% | 5.7% |
| Net margin | -1.1% | - | -23.5% | 13.6% | -7.9% | - | 21.9% | 11.8% | 0.1% | -10.4% |
| Free cash flow margin | 32.0% | - | - | - | 20.2% | - | - | - | 26.6% | - |
| FCF / Net income | -29.01 | - | - | - | -2.56 | - | - | - | 307.69 | - |
| R&D / Revenue | 19.0% | - | 15.3% | 13.4% | 18.0% | - | 16.5% | 15.6% | 17.4% | 14.7% |
| SG&A / Revenue | 60.3% | - | 93.5% | 56.5% | 60.0% | - | 39.7% | 51.0% | 60.2% | 53.7% |
| Effective tax rate | - | - | - | -35.0% | - | - | 14.3% | 24.3% | 49.0% | 261.6% |
| Return on assets | -0.2% | - | -3.2% | 1.6% | -0.9% | - | 2.9% | 1.5% | 0.0% | -1.2% |
| Return on equity | -0.2% | - | -4.3% | 2.1% | -1.1% | - | 3.8% | 2.1% | 0.0% | -1.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.96 | 1.90 | 1.80 | 2.58 | 2.44 | 2.35 | 2.20 | 1.91 | 1.88 | 1.56 |
| Quick ratio | 1.66 | 1.57 | 1.47 | 2.43 | 2.26 | 2.16 | 1.98 | 1.69 | 1.61 | 1.27 |
| Cash ratio | 0.49 | 0.38 | 0.46 | 0.51 | 0.41 | 0.24 | 0.11 | 0.17 | 0.26 | 0.33 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.39 | 1.37 | 1.35 | 1.30 | 1.31 | 1.32 | 1.33 | 1.37 | 1.39 | 1.41 |
| Liabilities / Assets | 0.28 | 0.27 | 0.26 | 0.23 | 0.23 | 0.24 | 0.25 | 0.27 | 0.28 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | 0.14 | - | 0.14 | 0.12 | 0.11 | - | 0.13 | 0.13 | 0.11 | 0.12 |
| Inventory turnover | 0.21 | - | 0.18 | 0.38 | 0.32 | - | 0.27 | 0.26 | 0.21 | 0.23 |
| Days sales outstanding | 320d | - | 325d | 311d | 355d | - | 302d | 331d | 375d | 336d |
| Days inventory outstanding | 1729d | - | 2061d | 955d | 1144d | - | 1328d | 1389d | 1732d | 1555d |
| Days payable outstanding | 159d | - | 157d | 178d | 164d | - | 133d | 94d | 322d | 63d |
| Cash conversion cycle | 1890d | - | 2229d | 1087d | 1335d | - | 1498d | 1625d | 1786d | 1828d |
| Valuation | ||||||||||
| P / E | - | - | - | 78.8x | - | - | 45.2x | 74.3x | - | - |
| P / B | 2.8x | - | 2.6x | 1.7x | 1.8x | - | 1.7x | 1.6x | 2.1x | 1.7x |
| P / S | 14.3x | - | 14.1x | 10.8x | 12.2x | - | 9.9x | 8.9x | 13.2x | 9.8x |
| EV / EBITDA | 157.0x | - | - | 129.8x | 169.2x | - | 41.4x | 62.1x | 103.6x | 161.4x |
| Growth | ||||||||||
| Revenue growth (YoY) | 38.6% | - | 9.3% | -1.7% | 4.3% | - | 14.2% | 24.2% | -6.6% | -13.2% |
| Revenue CAGR (3y) | 10.5% | - | 2.7% | -0.9% | -0.6% | - | 5.8% | 6.0% | 14.8% | -0.3% |
| Revenue CAGR (5y) | 16.9% | - | 4.4% | 5.5% | 9.5% | - | 11.5% | 10.0% | 10.9% | 8.4% |
| Gross profit growth (YoY) | 37.5% | - | 9.5% | -1.2% | 5.3% | - | 17.7% | 31.4% | -2.3% | -11.4% |
| Operating income growth (YoY) | 18.8% | - | - | -46.2% | -225.3% | - | 401.9% | - | - | - |
| Net income growth (YoY) | 80.6% | - | - | 13.0% | - | - | - | - | -99.3% | - |
| EPS growth (YoY) | 81.0% | - | - | 11.1% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | 41.9% | - | - | 19.9% | -5.8% | - | - |
| EPS CAGR (5y) | - | - | - | -9.3% | - | - | 5.0% | -10.0% | - | - |
| FCF growth (YoY) | 119.8% | - | - | - | -20.7% | - | - | - | -21.0% | - |
| FCF CAGR (5y) | 13.9% | - | - | - | 36.5% | - | - | - | 3.1% | - |
| Book value growth (YoY) | 4.5% | 2.5% | 4.2% | 11.1% | 11.8% | - | 10.4% | 4.1% | 1.0% | 7.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$718.95M totalReportable Segment$718.95M · 100.0%
Product / service
$1.35B totalProduct$626.54M · 46.6%
Qelbree$304.65M · 22.6%
GOCOVRI$146.82M · 10.9%
Collaboration Revenue$53.00M · 3.9%
APOKYN$47.77M · 3.6%
Trokendi Xr$42.42M · 3.2%
Oxtellar XR$40.70M · 3.0%
Royalty License And Other Revenue$39.42M · 2.9%
Manufactured Product Other$26.91M · 2.0%
ONAPGO$17.25M · 1.3%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing SUPERNUS PHARMACEUTICALS against the 5 most active filers in the same SIC group.